ADHD2
MCID: ATT020
MIFTS: 15

Attention Deficit-Hyperactivity Disorder 2 (ADHD2)

Categories: Genetic diseases, Mental diseases, Neuronal diseases

Aliases & Classifications for Attention Deficit-Hyperactivity Disorder 2

MalaCards integrated aliases for Attention Deficit-Hyperactivity Disorder 2:

Name: Attention Deficit-Hyperactivity Disorder 2 57
Attention Deficit-Hyperactivity Disorder, Susceptibility to, 2 57 13
Adhd2 57

Classifications:



External Ids:

OMIM 57 608904

Summaries for Attention Deficit-Hyperactivity Disorder 2

MalaCards based summary : Attention Deficit-Hyperactivity Disorder 2, also known as attention deficit-hyperactivity disorder, susceptibility to, 2, is related to attention deficit-hyperactivity disorder. An important gene associated with Attention Deficit-Hyperactivity Disorder 2 is ADHD2 (Attention Deficit-Hyperactivity Disorder, Susceptibility To, 2). The drugs Dopamine and Methylphenidate have been mentioned in the context of this disorder. Affiliated tissues include brain.

More information from OMIM: 608904

Related Diseases for Attention Deficit-Hyperactivity Disorder 2

Diseases in the Attention Deficit-Hyperactivity Disorder family:

Attention Deficit-Hyperactivity Disorder 1 Attention Deficit-Hyperactivity Disorder 2
Attention Deficit-Hyperactivity Disorder 3 Attention Deficit-Hyperactivity Disorder 4

Diseases related to Attention Deficit-Hyperactivity Disorder 2 via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 attention deficit-hyperactivity disorder 10.1

Symptoms & Phenotypes for Attention Deficit-Hyperactivity Disorder 2

Clinical features from OMIM:

608904

Drugs & Therapeutics for Attention Deficit-Hyperactivity Disorder 2

Drugs for Attention Deficit-Hyperactivity Disorder 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 7)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 2 51-61-6, 62-31-7 681
2
Methylphenidate Approved, Investigational Phase 2 113-45-1 4158
3 Neurotransmitter Agents Phase 2
4 Central Nervous System Stimulants Phase 2
5 Dopamine Agents Phase 2
6 Neurotransmitter Uptake Inhibitors Phase 2
7 Dopamine Uptake Inhibitors Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Effect of Methylphenidate on Ecologic Function in Paediatric Acquired Brain Injury Population Completed NCT02227056 Phase 2 Methylphenidate

Search NIH Clinical Center for Attention Deficit-Hyperactivity Disorder 2

Genetic Tests for Attention Deficit-Hyperactivity Disorder 2

Anatomical Context for Attention Deficit-Hyperactivity Disorder 2

MalaCards organs/tissues related to Attention Deficit-Hyperactivity Disorder 2:

41
Brain

Publications for Attention Deficit-Hyperactivity Disorder 2

Articles related to Attention Deficit-Hyperactivity Disorder 2:

(show all 12)
# Title Authors PMID Year
1
GIT1 is associated with ADHD in humans and ADHD-like behaviors in mice. 8
21499268 2011
2
Attention deficit hyperactivity disorder: fine mapping supports linkage to 5p13, 6q12, 16p13, and 17p11. 8
15297934 2004
3
A genomewide scan for attention-deficit/hyperactivity disorder in an extended sample: suggestive linkage on 17p11. 8
12687500 2003
4
Effective Use of Animal Models for Therapeutic Development in Psychiatric and Substance Use Disorders. 38
29478700 2018
5
Rates of peer victimization in young adolescents with ADHD and associations with internalizing symptoms and self-esteem. 38
27315106 2017
6
Adverse Health Effects Associated with Living in a Former Methamphetamine Drug Laboratory - Victoria, Australia, 2015. 38
28056000 2017
7
Extended-release Methylphenidate Treatment and Outcomes in Comorbid Social Anxiety Disorder and Attention-deficit/Hyperactivity Disorder: 2 Case Reports. 38
25955266 2015
8
Psychotropic drug use among preschool children in the Medicaid program from 36 states. 38
25602884 2015
9
The quality of life of adults with attention deficit hyperactivity disorder: a systematic review. 38
22808445 2012
10
Hematologic and blood biochemistry monitoring during methylphenidate treatment in children with attention-deficit/hyperactivity disorder: 2-year, open-label study results. 38
17548486 2007
11
Prader-Willi Syndrome: clinical concerns for the orthopaedic surgeon. 38
16932110 2006
12
[The course of behaviour changes in children with attention deficit and hyperactivity after drug treatment]. 38
12447796 2002

Variations for Attention Deficit-Hyperactivity Disorder 2

Expression for Attention Deficit-Hyperactivity Disorder 2

Search GEO for disease gene expression data for Attention Deficit-Hyperactivity Disorder 2.

Pathways for Attention Deficit-Hyperactivity Disorder 2

GO Terms for Attention Deficit-Hyperactivity Disorder 2

Sources for Attention Deficit-Hyperactivity Disorder 2

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....